Neith Corporation (TPEX:6236)
Taiwan · Delayed Price · Currency is TWD 25.60
0.00 (0.00%)
Jan 22, 2026, 9:04 AM CST
Neith Revenue
Neith had revenue of 7.51M TWD in the quarter ending September 30, 2025, a decrease of -22.52%. This brings the company's revenue in the last twelve months to 39.35M, down -6.55% year-over-year. In the year 2024, Neith had annual revenue of 45.57M with 14.20% growth.
Revenue (ttm)
39.35M
Revenue Growth
-6.55%
P/S Ratio
27.10
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.57M | 5.67M | 14.20% |
| Dec 31, 2023 | 39.90M | 7.85M | 24.48% |
| Dec 31, 2022 | 32.06M | 668.00K | 2.13% |
| Dec 31, 2021 | 31.39M | -12.35M | -28.24% |
| Dec 31, 2020 | 43.74M | 10.21M | 30.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 753.30M |
| Meribank Biotech | 486.52M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| TCI GENE | 324.73M |
| BioLASCO Taiwan | 277.12M |
| GeneReach Biotechnology | 215.32M |
| Lukas Biomedical | 180.32M |
| NatureWise Biotech & Medicals | 180.29M |